Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Wednesday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 2.9 %

Brooklyn ImmunoTherapeutics stock opened at $6.29 on Wednesday. Brooklyn ImmunoTherapeutics has a 12 month low of $5.10 and a 12 month high of $8.31. The stock has a market cap of $370.02 million, a price-to-earnings ratio of -2.77 and a beta of 4.61. The business has a 50 day moving average price of $6.31 and a two-hundred day moving average price of $2.55.

Brooklyn ImmunoTherapeutics Announces Dividend

The business also recently disclosed a monthly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, March 14th were paid a $0.0862 dividend. The ex-dividend date was Friday, March 14th. This represents a $1.03 annualized dividend and a dividend yield of 16.44%. Brooklyn ImmunoTherapeutics’s dividend payout ratio is currently -44.05%.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.